XBiotech Inc (XBIT) Director Sells $53,783.70 in Stock

Share on StockTwits

XBiotech Inc (NASDAQ:XBIT) Director W Thorpe Mckenzie sold 17,634 shares of XBiotech stock in a transaction that occurred on Wednesday, September 26th. The stock was sold at an average price of $3.05, for a total transaction of $53,783.70. Following the completion of the transaction, the director now owns 3,783,600 shares in the company, valued at approximately $11,539,980. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

W Thorpe Mckenzie also recently made the following trade(s):

  • On Thursday, September 13th, W Thorpe Mckenzie sold 49,584 shares of XBiotech stock. The stock was sold at an average price of $3.07, for a total transaction of $152,222.88.
  • On Monday, September 10th, W Thorpe Mckenzie sold 29,603 shares of XBiotech stock. The stock was sold at an average price of $3.31, for a total transaction of $97,985.93.
  • On Friday, August 10th, W Thorpe Mckenzie sold 9,809 shares of XBiotech stock. The stock was sold at an average price of $3.99, for a total transaction of $39,137.91.
  • On Wednesday, August 8th, W Thorpe Mckenzie sold 15,792 shares of XBiotech stock. The stock was sold at an average price of $3.97, for a total transaction of $62,694.24.
  • On Friday, August 3rd, W Thorpe Mckenzie sold 62,524 shares of XBiotech stock. The shares were sold at an average price of $3.98, for a total transaction of $248,845.52.
  • On Tuesday, July 31st, W Thorpe Mckenzie sold 11,875 shares of XBiotech stock. The shares were sold at an average price of $4.45, for a total transaction of $52,843.75.

Shares of NASDAQ:XBIT opened at $3.45 on Thursday. XBiotech Inc has a 12-month low of $2.13 and a 12-month high of $5.80.

Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in shares of XBiotech in the 2nd quarter valued at $931,000. Paloma Partners Management Co lifted its position in XBiotech by 479.1% during the 2nd quarter. Paloma Partners Management Co now owns 89,025 shares of the biopharmaceutical company’s stock worth $399,000 after acquiring an additional 73,652 shares during the last quarter. LMR Partners LLP acquired a new position in XBiotech during the 2nd quarter worth $154,000. Finally, Dimensional Fund Advisors LP lifted its position in XBiotech by 47.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 37,610 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 12,099 shares during the last quarter. 5.07% of the stock is owned by institutional investors and hedge funds.

XBiotech Company Profile

XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.

Recommended Story: How is a Moving Average Calculated?

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply